IOS sells innovative biological assays for a number of diagnostic applications. Immunoassays have gained popularity in recent years, as they offer fast and reliable measures of target markers through antibody high-affinity binding. Non-invasive testing of bone turnover biomarkers in saliva is an active research area at IOS.
Lateral flow assays represent the fastest and least costly diagnostic technology available for many screening applications. To bridge the gap between state-of-the-art ELISA lab testing and qualitative test-kit technologies, there has been a movement to introduce advanced point-of-care testing platforms that can collect and process measurements from small volumes of complex fluids quickly and efficiently, without the need for a highly-trained operator. Multiplexed tests are especially needed for routine point-of-care testing to accurately identify bone turnover markers by means of a single-step platform. The IOS salivary-based bone loss marker detection platform is well-suited for this application. This assay platform has following specific benefits:
- Multiplexed and accurate assays measure bone turnover markers for routine periodic POC testing;
- Saliva is a non-invasive, easily-obtained biofluid for convenient routine testing of large populations;
- The cost-effective test kit displays accurate measures of both osteoclast and osteoblast activities, indicating bone turnover status and signaling abnormalities for early treatment.